The proposed research is part of our ongoing research of the last 17 years. Development of immunotherapy for cancer is our main theme and DC vaccines is our oldest program and play a crucial role.At this moment still 40% of cancer patients die of…
ID
Source
Brief title
Condition
- Other condition
Synonym
Health condition
het betreft enkel afname van bloedcellen via aferese bij gezonde vrijwilligers voor verbeteren en optimaliseren productie methode cellulaire immunotherapie
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
The primary outcome that is relevant:
1. a strong T cell response in vitro with a readout of Interferon gamma
production.
Secondary outcome
NA
Background summary
The dendritic cell is the master switch of the immune system and the key player
in priming an immune response. In patients with established cancer, the
dendritic cells have not been able to initiate a potent enough immune response
or the tumor suppresses or deceives and escapes from the immune response.
Dendritic cell vaccines are developed to (re-)generate or initiate a strong
anti- tumor immune response.
Study objective
The proposed research is part of our ongoing research of the last 17 years.
Development of immunotherapy for cancer is our main theme and DC vaccines is
our oldest program and play a crucial role.
At this moment still 40% of cancer patients die of their disease. Het remains
therefore extremely urgent and relevant to acquire knowledge in this field that
can be used to ultimately be able to give new therapies to patients.
The current application proposed to the MECT has at the central aim to acquire
knowledge in the field that will allow us to further develop and improve our DC
vaccine in the laboratory. As it will later be applied in patients, the
material has to be of human origin.
The objective of the current study is to:
1. investigate the conditions to obtain the most optimal T cell stimulation in
vitro by the DC vaccine.
Study design
1. The study is an in vitro study. The apheresis product will be transfered to
the laboratory and white blood cells will be cultured in vitro. Monocytes will
be differentiated to dendritic cells that in turn will be used in T cell
stimulation assays.
Study burden and risks
The volunteers will receive a physical examination to determine their health
status and fitness for the apheresis process. At the same time one tube of
blood will be drawn and used to determine blood values. When donors are fit,
they will be subjected on a different day to the apheresis that will last for 4
hours. Before the start, one tube of heparinised blood will be drawn to
determine base values.
The risks for complications and side affects are very low, therefore the study
is justified.
Debyelaan 25
Maastricht 6229EV
NL
Debyelaan 25
Maastricht 6229EV
NL
Listed location countries
Age
Inclusion criteria
Healthy volunteers, no underlying disease
Age 18 or older
Male or Female
Exclusion criteria
no venous access
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL60859.068.17 |